Identification

Name
Dihydroergocristine
Accession Number
DB13345
Description

Dihydroergocristine is part of the ergoloid mixture products.7 It is a semisynthetic ergot alkaloid and thus, it is characterized by a structural skeleton formed by an alkaloid ergoline.1 To know more about ergoloid mixtures, please visit Ergoloid mesylate.

Type
Small Molecule
Groups
Approved, Experimental
Structure
Thumb
Weight
Average: 611.743
Monoisotopic: 611.31076944
Chemical Formula
C35H41N5O5
Synonyms
  • 9,10-dihydroergocristine
  • DHEC
External IDs
  • GNF-Pf-3462

Pharmacology

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Indication

Dihydroergocristine is used in some countries such as Brasil as a single agent for the treatment of cerebral and peripheric vascular events.8 To know more about dihydroergocristine as part of the ergoloid mesylate mixture, please visit Ergoloid mesylate.

Associated Conditions
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics

Dihydroergocristine has been shown to present effect on memory and cognition. This activity in the brain is been reported by an increase in glutathione in age-related brain states.2 The reported effect on serotonin and adrenergic receptors has also been correlated to an inhibition of platelet aggregation.8 It has also been reported that individuals exposed to dihydroergocristine may present an amphoteric vasoregulating activity either hypotensive in hypertensive individuals or hypertensive in hypotensive individuals.1 This action is performed by promoting a dilating action in the contracted arteries and a tonic action in the dilated arteries and arterioles.8 The vasoregulating effect causes an increase in cerebral blood flow and oxygen consumption by the brain, which correlates with the brain protective function of dihydroergocristine.2 In Alzheimer studies, dihydroergocristine reduced the amyloid-beta levels in different cell types.4 To know more about dihydroergocristine as part of the ergoloid mesylate mixture, please visit Ergoloid mesylate.

Mechanism of action

Dihydroergocristine mechanism of action seems to be related to a noncompetitive antagonistic activity in the serotonin receptors as well as a double partial agonist/antagonist activity in dopaminergic and adrenergic receptors.2 In Alzheimer studies, dihydroergocristine act as a direct inhibitor of γ-secretase.4

TargetActionsOrganism
ASerotonin Receptors
antagonist
Humans
ABeta adrenergic receptor
antagonist
agonist
Humans
AAlpha adrenergic receptor
antagonist
agonist
Humans
ADopamine receptor
antagonist
agonist
Humans
Absorption

Dihydroergocristine presents an absorption in the digestive tract of about 25% of the administered dose. When dihydroergocristine was orally administered in humans and the peak plasma concentration of 0.28 mcg/l was achieved after 0.46 hours. In the same report, the AUC was reported to be 0.39 mcg/l.h.3 To know more about dihydroergocristine as part of the ergoloid mesylate mixture, please visit Ergoloid mesylate.

Volume of distribution

Dihydroergocristine presents a large volume of distribution of 52 l/kg.6 To know more about dihydroergocristine as part of the ergoloid mesylate mixture, please visit Ergoloid mesylate.

Protein binding

Dihydroergocristine can be found in a bound state to plasma proteins in a proportion of even 68% of the administered dose.3 To know more about dihydroergocristine as part of the ergoloid mesylate mixture, please visit Ergoloid mesylate.

Metabolism

The major metabolite of dihydroergocristine is 8'-hydroxy-dihydroergocristine is produced in the liver.3 The modification of dihydroergocristine in the body is very extensive and it has been observed as an almost complete absence of the unchanged drug.6 To know more about dihydroergocristine as part of the ergoloid mesylate mixture, please visit Ergoloid mesylate.

Hover over products below to view reaction partners

Route of elimination

The most important elimination route of dihydroergocristine is in via the bile and it accounts for over 85% of the eliminated dose. Urine elimination accounts only for 5% of the administered dose.5 To know more about dihydroergocristine as part of the ergoloid mesylate mixture, please visit Ergoloid mesylate.

Half-life

The half-life of dihydroergocristine has only been studied as part of the therapeutic mixture, please refer to Ergoloid mesylate.

Clearance

Dihydroergocristine presents a high systemic clearance rate of 2.65 l/h.hg.6 To know more about dihydroergocristine as part of the ergoloid mesylate mixture, please visit Ergoloid mesylate.

Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity

Studies related to acute and chronic toxicity as well as teratogenesis and fertility has proven that dihydroergocristine is a non-toxic and very well tolerated drug.2 To know more about dihydroergocristine as part of the ergoloid mesylate mixture, please visit Ergoloid mesylate.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbametapirThe serum concentration of Dihydroergocristine can be increased when it is combined with Abametapir.
AbataceptThe metabolism of Dihydroergocristine can be increased when combined with Abatacept.
AbemaciclibThe metabolism of Abemaciclib can be decreased when combined with Dihydroergocristine.
AbirateroneThe metabolism of Dihydroergocristine can be decreased when combined with Abiraterone.
AcalabrutinibThe metabolism of Dihydroergocristine can be decreased when combined with Acalabrutinib.
AcebutololAcebutolol may increase the vasoconstricting activities of Dihydroergocristine.
AceclofenacThe risk or severity of hypertension can be increased when Aceclofenac is combined with Dihydroergocristine.
AcemetacinThe risk or severity of hypertension can be increased when Dihydroergocristine is combined with Acemetacin.
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Dihydroergocristine.
AcetaminophenThe metabolism of Dihydroergocristine can be increased when combined with Acetaminophen.
Interactions
Improve patient outcomes
Build effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.
Learn more
Food Interactions
No interactions found.

Products

Products
Comprehensive & structured drug product info
From application numbers to product codes, connect different identifiers through our commercial datasets.
Learn more
Easily connect various identifiers back to our datasets
Learn more
Product Ingredients
IngredientUNIICASInChI Key
Dihydroergocristine mesylateDS7CL18UAM24730-10-7SPXACGZWWVIDGR-SPZWACKZSA-N
International/Other Brands
Iskevert (Medley S/A)
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Ergoloid MesylatesDihydroergocristine mesylate (0.333 mg/1) + Dihydro-alpha-ergocryptine mesylate (0.222 mg/1) + Dihydroergocornine mesylate (0.333 mg/1) + Epicriptine mesilate (0.111 mg/1)TabletOralSun Pharmaceutical Industries Limited1991-10-31Not applicableUS flag
Ergoloid MesylatesDihydroergocristine mesylate (0.333 mg/1) + Dihydro-alpha-ergocryptine mesylate (0.333 mg/1) + Dihydroergocornine mesylate (0.333 mg/1)Tablet, orally disintegratingOralIVAX Pharmaceuticals, Inc.1980-11-202008-09-30US flag
Ergoloid MesylatesDihydroergocristine mesylate (0.333 mg/1) + Dihydro-alpha-ergocryptine mesylate (0.222 mg/1) + Dihydroergocornine mesylate (0.333 mg/1) + Epicriptine mesilate (0.111 mg/1)TabletOralCarilion Materials Management1991-10-31Not applicableUS flag
Ergoloid MesylatesDihydroergocristine mesylate (0.333 mg/1) + Dihydro-alpha-ergocryptine mesylate (0.222 mg/1) + Dihydroergocornine mesylate (0.333 mg/1) + Epicriptine mesilate (0.111 mg/1)TabletOralPhysicians Total Care, Inc.1991-10-312012-10-08US flag
Ergoloid MesylatesDihydroergocristine mesylate (0.333 mg/1) + Dihydro-alpha-ergocryptine mesylate (0.222 mg/1) + Dihydroergocornine mesylate (0.333 mg/1) + Epicriptine mesilate (0.111 mg/1)TabletOralFrontida BioPharm, Inc.2017-06-01Not applicableUS flag
Ergoloid MesylatesDihydroergocristine mesylate (0.333 mg/1) + Dihydro-alpha-ergocryptine mesylate (0.222 mg/1) + Dihydroergocornine mesylate (0.333 mg/1) + Epicriptine mesilate (0.111 mg/1)TabletOralAv Kare, Inc.2014-08-222015-09-15US flag
TOTERJİN DAMLA, 50 CCDihydroergocristine (33 %) + Dihydroergocryptine (33 %) + Ergoloid mesylate (33 %)Solution / dropsOralBİLİM İLAÇ SAN. VE TİC. A.Ş.2020-08-142018-08-16Turkey flag

Categories

ATC Codes
C04AE54 — Dihydroergocristine, combinationsC04AE04 — Dihydroergocristine
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as lysergamides. These are amides of Lysergic acids.
Kingdom
Organic compounds
Super Class
Alkaloids and derivatives
Class
Ergoline and derivatives
Sub Class
Lysergic acids and derivatives
Direct Parent
Lysergamides
Alternative Parents
Indoloquinolines / Benzoquinolines / Pyrroloquinolines / N-acyl-alpha amino acids and derivatives / 3-alkylindoles / Isoindoles and derivatives / Piperidinecarboxamides / Aralkylamines / N-alkylpiperazines / Benzene and substituted derivatives
show 17 more
Substituents
1,4-diazinane / 3-alkylindole / 3-piperidinecarboxamide / Alkanolamine / Alpha-amino acid or derivatives / Amine / Amino acid or derivatives / Aralkylamine / Aromatic heteropolycyclic compound / Azacycle
show 41 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
ergot alkaloid (CHEBI:59912)

Chemical Identifiers

UNII
05D48LUM4Z
CAS number
17479-19-5
InChI Key
DEQITUUQPICUMR-HJPBWRTMSA-N
InChI
InChI=1S/C35H41N5O5/c1-20(2)34(37-31(41)23-16-25-24-11-7-12-26-30(24)22(18-36-26)17-27(25)38(3)19-23)33(43)40-28(15-21-9-5-4-6-10-21)32(42)39-14-8-13-29(39)35(40,44)45-34/h4-7,9-12,18,20,23,25,27-29,36,44H,8,13-17,19H2,1-3H3,(H,37,41)/t23-,25-,27-,28+,29+,34-,35+/m1/s1
IUPAC Name
(2R,4R,7R)-N-[(1S,2S,4R,7S)-7-benzyl-2-hydroxy-5,8-dioxo-4-(propan-2-yl)-3-oxa-6,9-diazatricyclo[7.3.0.0^{2,6}]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0^{2,7}.0^{12,16}]hexadeca-1(16),9,12,14-tetraene-4-carboxamide
SMILES
[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)(O[C@@]21O)C(C)C

References

General References
  1. Drago F, Valerio C, Scalisi B, D'Agata V, Scapagnini U: Dihydroergocristine and memory alterations of aged male rats. Pharmacol Biochem Behav. 1988 Aug;30(4):961-5. [PubMed:3147464]
  2. Coppi G: [Dihydroergocristine. A review of pharmacology and toxicology]. Arzneimittelforschung. 1992 Nov;42(11A):1381-90. [PubMed:1492857]
  3. Bicalho B, Guzzo GC, Lilla S, Dos Santos HO, Mendes GD, Caliendo G, Perissutti E, Aiello A, Luciano P, Santagada V, Pereira AS, De Nucci G: Pharmacokinetics of dihydroergocristine and its major metabolite 8'-hydroxy-dihydroergocristine in human plasma. Curr Drug Metab. 2005 Dec;6(6):519-29. [PubMed:16379666]
  4. Lei X, Yu J, Niu Q, Liu J, Fraering PC, Wu F: The FDA-approved natural product dihydroergocristine reduces the production of the Alzheimer's disease amyloid-beta peptides. Sci Rep. 2015 Nov 16;5:16541. doi: 10.1038/srep16541. [PubMed:26567970]
  5. Nimmerfall F, Rosenthaler J: Ergot alkaloids: hepatic distribution and estimation of absorption by measurement of total radioactivity in bile and urine. J Pharmacokinet Biopharm. 1976 Feb;4(1):57-66. [PubMed:1271240]
  6. Grognet JM, Riviere R, Istin M, Zanotti A, Coppi G: [The pharmacokinetics of dihydroergocristine after intravenous and oral administration in rats]. Arzneimittelforschung. 1992 Nov;42(11A):1394-6. [PubMed:1492859]
  7. Dailymed [Link]
  8. ANVISA [Link]
KEGG Drug
D07834
ChemSpider
96884
BindingDB
50390992
RxNav
3416
ChEBI
59912
ChEMBL
CHEMBL601773
ZINC
ZINC000003995616
Wikipedia
Dihydroergocristine
MSDS
Download (76.2 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Solution / drops
TabletOral
Tablet, orally disintegratingOral
Solution / dropsOral
Tablet
Capsule
Tablet, sugar coatedOral
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)213-215 ºC'MSDS'
boiling point (°C)899.3 ºC at 760 mm HgProduct specifications
water solubility10 mg/ml'MSDS'
logP5.86Buckingham J. et al. Dictionary of Alkaloids.
pKa6.9Lemke T. and Williams D. Foye's Principles of Medicinal Chemistry.
Predicted Properties
PropertyValueSource
Water Solubility0.141 mg/mLALOGPS
logP3.56ALOGPS
logP3.83ChemAxon
logS-3.6ALOGPS
pKa (Strongest Acidic)9.71ChemAxon
pKa (Strongest Basic)8.39ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area118.21 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity168.28 m3·mol-1ChemAxon
Polarizability67.27 Å3ChemAxon
Number of Rings8ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Targets

Drugtargets
Accelerate your drug discovery research
with our fully connected ADMET & drug target dataset.
Learn more
Accelerate your drug discovery research with our ADMET & drug target dataset
Learn more
Kind
Protein group
Organism
Humans
Pharmacological action
Yes
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers...

Components:
References
  1. Coppi G: [Dihydroergocristine. A review of pharmacology and toxicology]. Arzneimittelforschung. 1992 Nov;42(11A):1381-90. [PubMed:1492857]
Kind
Protein group
Organism
Humans
Pharmacological action
Yes
Actions
Antagonist
Agonist
General Function
Receptor signaling protein activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately e...

Components:
References
  1. Coppi G: [Dihydroergocristine. A review of pharmacology and toxicology]. Arzneimittelforschung. 1992 Nov;42(11A):1381-90. [PubMed:1492857]
Kind
Protein group
Organism
Humans
Pharmacological action
Yes
Actions
Antagonist
Agonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...

Components:
References
  1. Coppi G: [Dihydroergocristine. A review of pharmacology and toxicology]. Arzneimittelforschung. 1992 Nov;42(11A):1381-90. [PubMed:1492857]
Kind
Protein group
Organism
Humans
Pharmacological action
Yes
Actions
Antagonist
Agonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.

Components:
References
  1. Coppi G: [Dihydroergocristine. A review of pharmacology and toxicology]. Arzneimittelforschung. 1992 Nov;42(11A):1381-90. [PubMed:1492857]

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Wooltorton E: Risk of stroke, gangrene from ergot drug interactions. CMAJ. 2003 Apr 15;168(8):1015. [PubMed:12695387]

Transporters

Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Substrate
General Function
Transporter activity
Specific Function
Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.
Gene Name
ABCB11
Uniprot ID
O95342
Uniprot Name
Bile salt export pump
Molecular Weight
146405.83 Da
References
  1. Pedersen JM, Matsson P, Bergstrom CA, Hoogstraate J, Noren A, LeCluyse EL, Artursson P: Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci. 2013 Dec;136(2):328-43. doi: 10.1093/toxsci/kft197. Epub 2013 Sep 6. [PubMed:24014644]

Drug created on June 23, 2017 20:40 / Updated on January 16, 2021 21:46